EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 3.0

17(R)-RvD1 Ameliorates Liver Injury in Hyperuricemia Through Inhibiting Pyroptosis via NF-κB Signaling Pathway

Lei Zhao iD, Yang Zhang iD, Yanling Qiao, Luyao Jia, Shenjian Luo iD

Drug Design, Development and Therapy · 2025

DOI: 10.2147/dddt.s524747 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Drug Design, Development and Therapy, 2025. Verfasst von Lei Zhao und 4 weiteren Autor:innen. Beteiligte Einrichtung: GMU-GIBH Joint School of Life Sciences, The Guangdong-Hong Kong-Macau Joint Laboratory for Cell Fate Regulation and Diseases, Guangzhou Medical Unive…. Hauptthemen laut MEDLINE: Hyperuricemia, Pyroptosis, NF-kappa B. Die Arbeit wurde bisher 4-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 3.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Purpose

The prevalence of hyperuricemia has been increasing worldwide. Most studies have focused on the influences of hyperuricemia on kidney damage and cardiovascular disease. However, the impacts of hyperuricemia on the liver remain unclear. 17(R)-RvD1 (Resolvin D1) plays a crucial role in various pathological conditions associated with inflammation. This study aims to investigate the effects of 17(R)-RvD1 on hyperuricemia-induced hepatic injury.

Methods

Potassium oxonate and hypoxanthine were used to establish a hyperuricemic mouse model and investigate the effects of 17(R)-RvD1 on hyperuricemia and concomitant liver injury. Serum uric acid, xanthine oxidase (XOD), alanine aminotransferase (ALT), aspartate aminotransferase (AST) and inflammatory cytokines levels were assessed. Hematoxylin-eosin (HE), Masson and Sirius Red staining were used to detect histological alterations in the liver. The mRNA and protein expression levels were determined by qRT-PCR and Western blot, respectively. Anti-inflammatory and anti-pyroptosis effects of 17(R)-RvD1 were also observed in LO2 cells exposed to uric acid.

Results

17(R)-RvD1 administration ameliorated serum uric acid, ALT, AST levels; decreased serum IL-1β, IL-6, TNF-α and IL-18 levels; mitigated hepatic inflammatory responses; reduced hepatic NLRP3, ASC and caspase-1 mRNA expression levels and c-caspase-1, IL-1β and IL-18 levels in hyperuricemic mice. Furthermore, 17(R)-RvD1 administration increased cell viability and reduced LDH release; decreased NLRP3, ASC and caspase-1 mRNA expression levels and Gasdermin D (GSDMD), c-caspase-1, IL-1β and IL-18 levels in LO2 cells exposed to uric acid. Finally, the anti-pyroptosis effects of 17(R)-RvD1 were blocked when the NF-κB signaling pathway was inhibited by BAY 11-7082.

Conclusion

17(R)-RvD1 possesses anti-hyperuricemic and anti-inflammatory effects, and the underlying mechanism for ameliorating hepatic injury in hyperuricemia is the inhibition of cell pyroptosis via downregulating the NF-κB signaling pathway. 17(R)-RvD1 could serve as an ideal candidate drug and increase options for the treatment of hyperuricemia.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

HyperuricemiaPyroptosisNF-kappa BAnimalsMiceSignal TransductionMaleMice, Inbred C57BLDisease Models, AnimalUric AcidDose-Response Relationship, DrugHumansStructure-Activity Relationship

Stichwörter der Autor:innen

17(R)-RvD1NF-κBhyperuricemialiver injurypyroptosis

Substanzen

NF-kappa BUric Acid

Autor:innen und Institutionen

  • GMU-GIBH Joint School of Life Sciences, The Guangdong-Hong Kong-Macau Joint Laboratory for Cell Fate Regulation and Diseases, Guangzhou Medical University, Guangzhou, 511436, People's Republic of China.
  • Department of Anesthesiology, First Affiliated Hospital of Nanchang University, Jiangxi Medical College, Nanchang University, Nanchang, 330006, People's Republic of China.
  • Department of Medicinal Chemistry and Natural Medicine Chemistry, College of Pharmacy, Harbin Medical University, Harbin, 150081, People's Republic of China.
  • Department of Ultrasound, Shenzhen Baoan People's Hospital, Second Affiliated Hospital of Shenzhen University, Shenzhen, 518035, People's Republic of China.
  • Department of Endocrinology and Metabolism, Nanfang Hospital, Southern Medical University, Guangzhou, 510515, People's Republic of China.

ORCID-Profile: Lei Zhao, Yang Zhang, Shenjian Luo

Zitieren

APA

Zhao, L., Zhang, Y., Qiao, Y., Jia, L., & Luo, S. (2025). 17(R)-RvD1 Ameliorates Liver Injury in Hyperuricemia Through Inhibiting Pyroptosis via NF-κB Signaling Pathway. Drug Design, Development and Therapy. https://doi.org/10.2147/dddt.s524747

Vancouver

Zhao L, Zhang Y, Qiao Y, Jia L, Luo S. 17(R)-RvD1 Ameliorates Liver Injury in Hyperuricemia Through Inhibiting Pyroptosis via NF-κB Signaling Pathway. Drug Design, Development and Therapy. 2025. doi:10.2147/dddt.s524747

BibTeX
@article{Zhao2025,
  author = {Zhao, Lei and Zhang, Yang and Qiao, Yanling and Jia, Luyao and Luo, Shenjian},
  title = {17(R)-RvD1 Ameliorates Liver Injury in Hyperuricemia Through Inhibiting Pyroptosis via NF-κB Signaling Pathway},
  journal = {Drug Design, Development and Therapy},
  year = {2025},
  doi = {10.2147/dddt.s524747}
}
Kostenlos starten →